

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K/A  
(Amendment No. 1)**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 21, 2021**

**LOGICBIO THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-38707**  
(Commission  
File Number)

**47-1514975**  
(IRS Employer  
Identification No.)

**65 Hayden Avenue, 2nd Floor  
Lexington, MA**  
(Address of principal executive offices)

**02421**  
(Zip Code)

**(617) 245-0399**  
(Registrant's telephone number, including area code)

**n/a**  
(Former name, former address and formal fiscal year, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Common Stock, par value \$0.0001 per share</b>	<b>LOGC</b>	<b>The Nasdaq Global Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 22, 2021, LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) disclosing that, on and effective December 21, 2021, the Board of Directors of the Company (the “Board”) increased the Board’s size from eight to nine directors and appointed Susan R. Kahn to serve as a Class II director. Committee assignments for Ms. Kahn were not determined as of the filing of the Original Form 8-K.

This Current Report on Form 8-K/A hereby amends Item 5.02 of the Original Form 8-K to disclose that, on and effective March 17, 2022, the Board appointed Ms. Kahn to serve on the Nominating and Corporate Governance Committee of the Board.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 18, 2022

LOGICBIO THERAPEUTICS, INC.

By: /s/ Cecilia Jones

Name: Cecilia Jones

Title: Chief Financial Officer